NEULAND LABORATORIES
|
|
BOM : 524558     NSE : NEULANDLAB     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Downward Pledged Shares : None or < 25% |
Oct 07,2024 |
Price(EOD): ₹ 11,353.80
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 14,532.86 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
NEULAND LABORATORIES | -8.4% | -11.3% | 223.7% |
SUN PHARMACEUTICAL INDUSTRIES | -1.1% | 4.4% | 67.3% |
CIPLA | -1.8% | -0.2% | 37.2% |
DR REDDYS LABORATORIES | -2.3% | -1.4% | 21.5% |
ZYDUS LIFESCIENCES | -1.6% | -5.8% | 73.2% |
DIVIS LABORATORIES | -0.8% | 5.4% | 45.7% |
FUNDAMENTAL ANALYSIS OF NEULAND LABORATORIES
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF NEULAND LABORATORIES
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
43.34
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 336.07 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 11.36
P/B Calculated based on Book Value of Rs 1,282.70 Cr
[Latest Year - Mar2024 - Consolidated Results ] 8.91
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 1,635.19 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
477% 383% 509% |
SHARE PRICE MOMENTUM OF NEULAND LABORATORIES
NEULAND LABORATORIES vs SENSEX
DEBT OF NEULAND LABORATORIES
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.06 0.12 0.28 0.15 |
0.06 0.12 0.28 0.15 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF NEULAND LABORATORIES
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF NEULAND LABORATORIES
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
14.18% 15.38% 40.82% 44.86% |
21.1% 27.28% 56.13% 58.17% |
QtrlyTrend |
8 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
NEULAND LABORATORIES related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE HEALTHCARE | -3% | -0.7% | 51.3% |
S&P BSE MIDSMALLCAP | -5.1% | -3.9% | 44.8% |
S&P BSE SMALL CAP | -5.2% | -3.7% | 44.1% |
S&P BSE ALLCAP | -5.4% | -2.6% | 34.2% |
You may also like the below Video Courses
FAQ about NEULAND LABORATORIES
Is NEULAND LABORATORIES good for long term investment?
As on Oct 07,2024, the Fundamentals of NEULAND LABORATORIES look Strong and hence it may be good for long term investment! See Financial Performance of NEULAND LABORATORIES . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is NEULAND LABORATORIES UnderValued or OverValued?
As on Oct 07,2024, NEULAND LABORATORIES is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of NEULAND LABORATORIES ?
As on Oct 07,2024, the Intrinsic Value of NEULAND LABORATORIES is Rs. 1,968.15 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 1,968.15
Fair Value [Median EV / Sales Model] : Rs. 2,348.71
Fair Value [Median Price / Sales Model] : Rs. 1,863.20
Estimated Median Fair Value of NEULAND LABORATORIES : Rs. 1,968.15
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.